Wick Capital Partners’s BioMarin Pharmaceuticals BMRN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$204K Sell
3,397
-290
-8% -$18.3K 0.03% 327
2026
Q2
$211K Sell
3,687
-892
-19% -$48.9K 0.03% 232
2026
Q1
$259K Buy
4,579
+266
+6% +$15.5K 0.05% 179
2025
Q4
$256K Buy
+4,313
New +$235K 0.05% 167

Other funds holding BMRN

Wick Capital Partners's BMRN Position: Q3 2026 in Review

Wick Capital Partners reduced its BioMarin Pharmaceuticals (BMRN) stake by 7.9% in Q3 2026, selling an estimated $18.3K and leaving 3,397 shares worth $204K. The position accounts for 0.03% of the portfolio, ranked #327.

Wick Capital Partners first reported a position in BMRN in Q4 2025 and has held it in 4 quarters since. The position peaked at $259K in Q1 2026. 567 funds tracked by Wall St. Rank hold BMRN as of Q3 2026.

  • Wick Capital Partners held 3,397 shares of BioMarin Pharmaceuticals worth $204K as of Q3 2026.
  • Wick Capital Partners sold 290 BioMarin Pharmaceuticals shares in Q3 2026, an estimated $18.3K.
  • BioMarin Pharmaceuticals made up 0.03% of Wick Capital Partners's portfolio in Q3 2026, its #327 holding.
  • Wick Capital Partners first reported a position in BioMarin Pharmaceuticals in Q4 2025 and has held it in 4 quarters since.
  • Wick Capital Partners's BioMarin Pharmaceuticals position peaked at $259K in Q1 2026.
  • 567 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2026.

Based on Wick Capital Partners's 13F filing for Q3 2026, filed 16 Nov 2026.